AZD0901 Compared With Investigator’s Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

AZD0901 Compared With Investigator’s Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Conditions: Gastric Cancer; Gastroesophageal Junction Cancer

Interventions: Drug: AZD0901; Drug: AZD0901; Drug: Ramucirumab+ paclitaxel; Drug: Paclitaxel; Drug: Docetaxel; Drug: Irinotecan; Drug: TAS-102; Drug: Apatinib

Sponsors: AstraZeneca

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 5, 2024Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments